The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform
about
Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approachAssessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patientsCurrent perspectives on interferon Beta-1b for the treatment of multiple sclerosisLong-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort studyDifferential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug.Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary.Characteristics and predictors of progression in an Egyptian multiple sclerosis cohort: a multicenter registry study.Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs.Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studies.Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.Management of multiple sclerosis patients in central European countries: current needs and potential solutions.Treatment satisfaction and quality of life in patients treated with fingolimod.
P2860
Q28080043-76B0E66F-A051-4DE4-8503-D67718A30EBBQ33764067-AF733150-0884-46C9-A0FB-C8367FBAC177Q34253488-569DEDAF-68BF-49B0-830D-FDBA0A1C5E46Q35388991-DB2BE93B-6C35-4EC5-8236-C6FECBBC1588Q35749670-4017511F-3FC3-4F44-94D6-32D5D5E6F5FAQ37573148-FF18CAAB-6F94-4D94-8C2E-233FBCB1C75DQ38393505-2FCD7C5D-1F3B-4421-827E-1CA7E3695E28Q38647849-18BC7DB3-F9CB-4333-8A60-EF4CF9DA0154Q39025672-D583D10F-B9E6-4791-9C77-23E1B3891CD1Q39061969-58590826-5A12-460B-B6AE-6A3A8B9ABDA8Q39234479-0023CD49-745F-4C21-AAB6-A5AD37AC323FQ40710140-DED95208-6434-4FB7-B3B3-26F701D05D5CQ41611259-512E48B2-F06F-4982-AD82-BEBC4300936BQ52365115-15B25507-291A-4AFC-B898-34780B462A69Q55314123-D7C3146F-DD12-4369-AA54-AC9C5475F14E
P2860
The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The Australian Multiple Sclero ...... tion using the MSBase platform
@ast
The Australian Multiple Sclero ...... tion using the MSBase platform
@en
The Australian Multiple Sclero ...... tion using the MSBase platform
@nl
type
label
The Australian Multiple Sclero ...... tion using the MSBase platform
@ast
The Australian Multiple Sclero ...... tion using the MSBase platform
@en
The Australian Multiple Sclero ...... tion using the MSBase platform
@nl
prefLabel
The Australian Multiple Sclero ...... tion using the MSBase platform
@ast
The Australian Multiple Sclero ...... tion using the MSBase platform
@en
The Australian Multiple Sclero ...... tion using the MSBase platform
@nl
P2093
P2860
P50
P921
P3181
P1433
P1476
The Australian Multiple Sclero ...... tion using the MSBase platform
@en
P2093
Australian Msbase Study Group
Cameron Shaw
Jeannette Lechner-Scott
Michael Barnett
Tim Spelman
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0059694
P407
P577
2013-03-19T00:00:00Z